Business

Novartis reportedly nears deal to buy cholesterol drugmaker Medicines Company for $7 billion

A logo sits on display on a building at the Novartis AG campus in Basel, Switzerland, on Wednesday, Jan. 16, 2019.

Stefan Wermuth | Bloomberg | Getty Images

Swiss pharmaceutical giant Novartis is close to a deal to purchase the cholesterol drugmaker Medicines Company for nearly $7 billion, according to The Wall Street Journal, which cited people familiar with the matter.

Novartis has agreed to pay $85 a share for Medicines Company in a deal that could be reached this weekend, according to The Journal.

The deal would strengthen the Swiss pharma giant’s position in the market for heart treatments, The Journal reported. Novartis, which has a market value of over $200 billion, is already targeting that market with drugs such as the heart-failure treatment Entresto. 

However, Entresto’s early sales have not met Wall Street’s expectations, according to The Journal, though prescriptions have picked up with sales jumping to $430 million in the third quarter. 

Medicines closed down nearly 2% Friday at 68.55 a share. The company, which has a market cap of about $5.4 billion, is up 258% year to date. 

Read the full story in The Wall Street Journal

Products You May Like

Articles You May Like

Amazon, Google, Meta, Microsoft lay off thousands — but tech jobs are still hot in 2023, Indeed finds
Cramer’s week ahead: Fed decision on Wednesday could let the bulls ‘party on’
Biden-⁠Harris Administration Announces New Actions To Protect Renters And Promote Rental Affordability
SECURE 2.0 Glitch Appears To Remove Your Ability To Make Retirement Catch-Up Contributions In 2024
Retirees Must Ask These Questions Before Hiring A Financial Professional

Leave a Reply

Your email address will not be published. Required fields are marked *